CzMA JEP Home page CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ
Journals - Article
CzMA JEP Home page News About Assocation Publishing Division Medical Journals Searching Supplements Catalogue
 
  Česky / Czech version Čas. Lék. čes., 142, 2003, No. 8, p. 500–504.
 
Long-Lasting Combination Treatment of Mixed Hyperlipoproteinaemias with Statins and Fibrates 
Zeman M., Žák A., Vecka M., Romaniv S. 

IV. interní klinika 1. LF UK a VFN, Praha
 


Summary:

       Background. It is difficult to achieve satisfactory decreases of both plasma LDL-cholesterol (LDL-C) and triglycerides (TG) and increase of HDL-C with only single statin or fibrate treatment of patients with mixed hyperlipoproteinaemias (HLP). Combination treatment with both statin and fibrate has been shown to enhance achieving of recommended targets in these patients with high-risk of coronary heart disease. On the other hand unpleasant side effects including myopathy and rhabdomyolysis were described in some cases after statin-fibrate combination therapy. Aim of the study was to evaluate efficacy and safety of long-term treatment of pravastatin+fenofibrate or simvastatin+ciprofibrate therapy in the high-risk group of patients with severe mixed hyperlipoproteinemia. Methods and Results. A set of 86 patients (55 M/31 F) was followed for a period at least one year (median 3 years). These patients were randomly assigned to combination of pravastatin 20 mg + fenofibrate 200mg (n=46) (group A), or simvastatin 20 mg + ciprofibrate 100 mg (n=40) (group B). We have observed significant reduction in plasma TC (22 % in group A, 20 % in group B), in LDL-C (36 %, resp. 33 %), reduction of TG (44 %, resp. 46 %), apo-B (35 %, resp. 33 %) whilst HDL-C significantly increased (18 %, resp. 16 %). Concomitantly we have seen significant decreases in uricaemia (14 %, resp. 18 %). No patient needed to stop treatment due to abnormalities in liver function tests. Levels of creatinkinase became non-significantly elevated (by 16%, resp. 13%).No patient exhibitedmyopathy or rhabdomyolysis. Conclusions. The long-term combined therapy with statin-fibrate (pravastatin 20 mg + fenofibrate 200 mg, or simvastatin 20 mg + ciprofibrate 100 mg) in severe mixed HLP was safe and effectively improved plasma lipid and apolipoprotein levels. Both combinations seemed to be similarly efficient and safe.

        Key words: combination hypolipidemic therapy, statins, fibrates, mixed hyperlipoproteinemia.
       

Order this issue

  BACK TO CONTENTS  
 
 
| HOME PAGE | CODE PAGE | CZECH VERSION |
©  1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o.
WEBMASTER